Welcome to our dedicated page for Spectral AI news (Ticker: MDAI), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.
Spectral AI, Inc. develops artificial intelligence medical diagnostics for wound care, with the DeepView System as its principal platform for burn-wound assessment. DeepView combines multispectral imaging with a proprietary AI algorithm to evaluate the healing potential of burn wounds and provide a binary prediction on whether tissue is likely to heal within a specified period.
Recurring news about Spectral AI covers DeepView presentations at burn-care medical meetings, BARDA funding for burn imaging technology, FDA De Novo 510(k) activity, financial results, commercialization preparation, stockholder meetings and executive appointments. Company updates also describe research and development revenue tied to government-supported development work and governance matters associated with its Nasdaq-listed common stock.
Spectral AI (Nasdaq: MDAI) announced that David McGuire, CPA, will join as Chief Financial Officer effective May 4, 2026. The appointment highlights experience in public company reporting, Sarbanes-Oxley 404, capital markets and finance transformation as the company readies commercialization of the DeepView® System.
Mr. McGuire has over 20 years of finance and accounting experience, including senior roles at Solo Brands, EZCORP and Ernst & Young, and holds a BBA and a Master in Professional Accounting from The University of Texas at Austin.
Spectral AI (Nasdaq: MDAI) reported Q4 2025 R&D revenue $3.8M and FY 2025 R&D revenue $19.7M. Cash was $15.4M at December 31, 2025, and Q4 net income was $0.6M while FY net loss was $(7.6M). The company submitted a De Novo 510(k) for DeepView burn indication and received $31.7M additional BARDA funding, with $54.9M committed to date under a contract valued up to $150M. Spectral AI provided 2026 revenue guidance of approximately $18.5M.
Spectral AI (Nasdaq: MDAI) received $31.7 million from BARDA to accelerate feature development of its DeepView® System, an AI burn wound imaging platform. The company will add $9.7 million toward development; BARDA funding supplements $54.9 million previously committed under a contract valued up to $150.0 million. The award is non-dilutive as Spectral AI awaits a determination on market authorization from the U.S. FDA for DeepView.
Spectral AI (Nasdaq: MDAI) will report fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026 after market close. A conference call to discuss results will be held the same day at 5:00 PM ET. Investors may dial in or join a simultaneous webcast via the company investor events page.
Dial-in: 833-890-6620 (U.S.), 412-564-3789 (International). Webcast available at the company’s Investor Relations Events page.
Spectral AI (Nasdaq: MDAI) appointed Vincent S. Capone as Chief Executive Officer effective February 9, 2026, promoting its CFO and general counsel as the company shifts toward commercialization of its DeepView® non-invasive, AI-driven burn wound assessment device.
The company highlighted its June 2025 FDA submission as a major milestone and said the leadership change will support commercial execution with the chairman remaining as executive chairman.
Spectral AI (Nasdaq: MDAI) will participate in National Burn Awareness Week, Feb 1–7, 2026, partnering with the American Burn Association to promote workplace burn prevention and employee education.
The company highlighted internal events, leadership messages, engineer stories, and burn-safety tips, and referenced its June 2025 De Novo submission to the FDA for the DeepView System.
Spectral AI (Nasdaq: MDAI) showcased its DeepView System at the Southern Region Burn Conference in Charleston (Oct 30–Nov 2, 2025) and will be highlighted at the Northeast Region Burn Conference in Washington, DC (Nov 21–22, 2025).
The DeepView System was featured in sessions on initial cost savings, AI training methodology, and clinician decision accuracy under a “wait-and-see” approach. Company leaders and clinicians emphasized evidence-based burn assessment and physician collaboration to improve patient outcomes and introduce the technology to the market.
Spectral AI (NASDAQ: MDAI) reported third-quarter 2025 results for the period ended September 30, 2025, highlighting Q3 R&D revenue of $3.8 million and YTD revenue of $15.6 million. Cash improved to $10.5 million as of Sept 30, 2025 (flat vs Q2 2025; up from $3.7M in Q3 2024). The company recorded a Q3 net loss of $3.6 million versus $1.5 million a year earlier, driven by a 54% decline in R&D revenue after its June De Novo submission to the FDA.
After quarter close (Oct 22, 2025) Spectral entered a securities purchase agreement raising ~$7.6 million gross via common shares, warrants and pre-funded warrants. Full-year revenue guidance was lowered from $21.5M to $18.5M, citing BARDA timing and a U.S. government shutdown impact.
Spectral AI (Nasdaq: MDAI) will report third quarter financial results for the period ended September 30, 2025 on Tuesday, November 11, 2025 after market close. The company will host a conference call the same day at 5:00 PM ET to discuss results. Investors can join by dialing 833-630-1956 (U.S.) or 412-317-1837 (International), or via a simultaneous webcast available on the company’s Investor Relations Events & Presentations page at https://investors.spectral-ai.com/news-events/events.
Spectral AI (Nasdaq: MDAI) priced a $7.6 million offering on October 23, 2025 to fund expansion of its DeepView® System. The financing includes the issuance of 4,000,000 shares of common stock and pre-funded warrants at $1.90 per share, plus corresponding warrants with an exercise price of $2.51 per share.
The company said proceeds will support continued development, broaden clinical indications, and prepare for commercial readiness in 2026, while maintaining support for its BARDA Project BioShield contract. Northland Capital Markets served as exclusive placement agent and Reed Smith served as counsel.